Literature DB >> 23417045

[Diagnostics of benign prostate syndrome].

M Seitz1, A Herlemann, G Magistro, C G Stief.   

Abstract

The diagnostic work-up of lower urinary tract symptoms (LUTS) in the German guidelines consists of obligatory and optional diagnostic parameters. Recommendations for assessing LUTS include patient history, symptom questionnaires (IPSS international prostate symptoms score), physical examination, urine analysis, prostate-specific antigen, uroflowmetry, ultrasound examination of the urinary bladder, including postvoid residual urine and ultrasound examination of the upper urinary tract. Optional tests are voiding diary, pressure-flow studies, ultrasound measurement of detrusor wall thickness, urethrocystography and urethrocystoscopy. Ultrasound measurement of detrusor wall thickness in particular has a 95 % positive predictive value in diagnosing bladder outlet obstruction. With all diagnostic parameters it is possible to treat LUTS in a risk-adapted manner.

Entities:  

Mesh:

Year:  2013        PMID: 23417045     DOI: 10.1007/s00120-012-3085-1

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  29 in total

1.  [Guidelines for German urologists on diagnosis of benign prostate syndrome].

Authors:  R Berges; K Dreikorn; K Höfner; U Jonas; K U Laval; S Madersbacher; M C Michel; R Muschter; M Oelke; L Pientka; C Tschuschke; U Tunn; K Schalkhäuser; B Göckel-Beining; A Heidenreich; H Rübben; K Schalkhäuser; W Thon; J Thüroff; W Weidner
Journal:  Urologe A       Date:  2003-03-12       Impact factor: 0.639

2.  Post-void residual urine volume is not a good predictor of the need for invasive therapy among patients with benign prostatic hyperplasia.

Authors:  C A Mochtar; L A L M Kiemeney; M M van Riemsdijk; M P Laguna; F M J Debruyne; J J M C H de la Rosette
Journal:  J Urol       Date:  2006-01       Impact factor: 7.450

3.  'Prostate-related symptoms' in Canadian men 50 years of age or older: prevalence and relationships among symptoms.

Authors:  R W Norman; J C Nickel; D Fish; S N Pickett
Journal:  Br J Urol       Date:  1994-11

Review 4.  The progression of benign prostatic hyperplasia: examining the evidence and determining the risk.

Authors:  J B Anderson; C G Roehrborn; J A Schalken; M Emberton
Journal:  Eur Urol       Date:  2001-04       Impact factor: 20.096

5.  Prediction of prostate volume based on total and free serum prostate-specific antigen: is it reliable?

Authors:  J Morote; G Encabo; M López; I M de Torres
Journal:  Eur Urol       Date:  2000-07       Impact factor: 20.096

6.  Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study.

Authors:  Debra E Irwin; Ian Milsom; Steinar Hunskaar; Kate Reilly; Zoe Kopp; Sender Herschorn; Karin Coyne; Con Kelleher; Christian Hampel; Walter Artibani; Paul Abrams
Journal:  Eur Urol       Date:  2006-10-02       Impact factor: 20.096

7.  Natural history of benign prostatic hyperplasia and risk of prostatectomy. The Baltimore Longitudinal Study of Aging.

Authors:  H M Arrighi; E J Metter; H A Guess; J L Fozzard
Journal:  Urology       Date:  1991       Impact factor: 2.649

8.  Relationship between age, prostate volume, prostate-specific antigen, symptom score and uroflowmetry in men with lower urinary tract symptoms.

Authors:  Stepan Vesely; Tomas Knutson; Jan-Erik Damber; Mauro Dicuio; Christer Dahlstrand
Journal:  Scand J Urol Nephrol       Date:  2003

Review 9.  The long-term outcome of medical therapy for BPH.

Authors:  Stephan Madersbacher; Martin Marszalek; Jakob Lackner; Peter Berger; Georg Schatzl
Journal:  Eur Urol       Date:  2007-03-28       Impact factor: 20.096

10.  Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7).

Authors:  Raymond Rosen; Jens Altwein; Peter Boyle; Roger S Kirby; B Lukacs; Eric Meuleman; Michael P O'Leary; Paolo Puppo; Chris Robertson; Francois Giuliano
Journal:  Eur Urol       Date:  2003-12       Impact factor: 20.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.